Mpox: there is still risk of global outbreak DOI
Silvano Esposito,

Chiara D’Amore,

Francesco Antonio Salzano

et al.

Journal of Chemotherapy, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 10

Published: March 13, 2025

Mpox is an emerging zoonosis that was first described in African animals, including monkeys, small rodents, and Gambian marsupial rats. It has since been identified as a sexually transmitted infection among humans. The disease characterized by incubation period ranging from 5 to 21 days, with the prodromal phase typically presenting nonspecific symptoms. followed development of characteristic vesicular skin lesions are hallmarks Mpox. Over years, outbreaks have occurred regularly Central West Africa. In July 2022, World Health Organization (WHO) declared outbreak Public Emergency International Concern (PHEIC), due rapid spread virus non-endemic countries. On May 11, 2023, WHO end emergency, considering significant decline reported cases. As October 2024, true impact this on international public health remains unclear.

Language: Английский

Immunobiology of MPox Infection and Its Management: Experience From Developing Nations DOI
Om Saswat Sahoo,

Daina Sapam,

Swati Ajmeria

et al.

Reviews in Medical Virology, Journal Year: 2025, Volume and Issue: 35(1)

Published: Jan. 1, 2025

ABSTRACT Purpose As humanity grapples with the COVID‐19 pandemic caused by novel SARS‐CoV‐2 virus, rising threats of MPox virus (MPXV) in 2022 and 2024 have shown signs global transmission potential to spark another pandemic. Though MPXV has been present for over 5 decades, cases traditionally confined endemic regions West Central Africa, recent outbreaks occurred multiple non‐endemic regions, declaring itself as a Public Health Emergency International Concern. This study aims examine patterns transmission, its zoonotic potential, associated complications, viable strategies control spread. Methods The examines outbreak data, case reports, literature on emphasising pathways healthcare‐associated cases. A bibliometric analysis also performed deepen understanding identify emerging research trends. Results findings suggest that while certain indicate an increased risk countries, raising concerns about Data reveals much within healthcare settings. Additionally, remains limited requires further exploration from various perspectives, need prompt intervention. Conclusion Containing MPXV's spread is essential prevent Effective management strategies, including enhanced surveillance, public health interventions, targeted education at‐risk communities, are critical mitigate impact globally. advocates proactive approach avoid escalation into widespread crisis.

Language: Английский

Citations

0
Real-world application of molecular docking in drug discovery DOI
Somenath Dutta,

Indrani Biswas,

Subhabrata Goswami

et al.

Advances in pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0
Xmas‐NT: A Novel Two‐Color Fluorescence Micro Neutralization Test for the Detection of Neutralizing Antibodies Against Monkeypox Virus DOI Creative Commons

Clemens Bodenstein,

Daniel Bourquain, Andreas Nitsche

et al.

Journal of Medical Virology, Journal Year: 2025, Volume and Issue: 97(2)

Published: Feb. 1, 2025

Since the global outbreak of Mpox in 2022, interest seroepidemiological and vaccine studies has grown rapidly. One aspect these is detection neutralizing antibodies to causative agent, monkeypox virus (MPXV). Determination using a (micro)-neutralization test (NT) gold standard method, which time consuming labor intensive. Here, we present comparison different methods facilitate MPXV NT analysis resulting establishment an optimized protocol. The protocol based on recombinant eGFP-expressing mCherry-expressing VeroE6 cell line. Using so-called Xmas-NT, incubation can be reduced by 60%. In addition, compared conventional NT, documentation Xmas-NT significantly 80%, making it suitable for serological high throughput screening studies.

Language: Английский

Citations

0
From pox to protection: understanding Monkeypox pathophysiology and immune resilience DOI Creative Commons

Alagammai Ganesan,

Thirumalai Arunagiri,

Suganandhini Mani

et al.

Tropical Medicine and Health, Journal Year: 2025, Volume and Issue: 53(1)

Published: Feb. 26, 2025

Abstract The Monkeypox virus (MPXV), which causes (Mpox) is an invasive ailment with global implications. MPXV, categorized within the Orthopoxvirus genus, exhibits diverse clades varying fatality rates. Initially discovered in monkeys and later humans, disease predominantly affects regions across West Central Africa. Clinical manifestations encompass a spectrum from mild flu-like symptoms to severe eruptions. This article aims give scientific community comprehensive overview of Mpox Pathophysiology delve into intricate landscape host immune responses against MPXV infection. It offers crucial insights virus's Pathophysiology, spanning its entry, replication, dissemination, elicited responses. reaction involves innate immunity, B-cell T-cell immunity. Moreover, this review underscores immunological response resistance mechanisms MPXV. also highlights imperative research areas warranting prioritization devise more efficacious treatments for controlling viral propagation healthcare systems. In addition, it gives us look possible futures that could help progress immunotherapies cutting-edge biotechnological solutions protecting

Language: Английский

Citations

0
Mpox: there is still risk of global outbreak DOI
Silvano Esposito,

Chiara D’Amore,

Francesco Antonio Salzano

et al.

Journal of Chemotherapy, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 10

Published: March 13, 2025

Mpox is an emerging zoonosis that was first described in African animals, including monkeys, small rodents, and Gambian marsupial rats. It has since been identified as a sexually transmitted infection among humans. The disease characterized by incubation period ranging from 5 to 21 days, with the prodromal phase typically presenting nonspecific symptoms. followed development of characteristic vesicular skin lesions are hallmarks Mpox. Over years, outbreaks have occurred regularly Central West Africa. In July 2022, World Health Organization (WHO) declared outbreak Public Emergency International Concern (PHEIC), due rapid spread virus non-endemic countries. On May 11, 2023, WHO end emergency, considering significant decline reported cases. As October 2024, true impact this on international public health remains unclear.

Language: Английский

Citations

0